Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preservative-free Tafluprost/Timolol FDC in Glaucoma or Ocular Hypertension
NCT01292460Phase 3Completed
- Sponsor
- Santen Pharmaceutical
- Start
- Feb 2011
- Primary completion
- Sep 2012
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tafluprost and timolol in open-angle glaucoma (OAG) and ocular hypertension (4 arms), sponsored by Santen Pharmaceutical. Primary endpoint: Change from baseline in the average diurnal Intraocular Pressure (IOP) at 3 months. Started Feb 2011; status: completed.
02
Drugs
tafluprosttimolol
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on NCT01292460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01292460.